🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Robert Chen

Xuzhou Medical College

ORCID: 0000-0002-2714-2434

Also affiliated with The First People’s Hospital of Lianyungang, AstraZeneca (United States), Stony Brook University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE”.

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood(2022)10.1182/blood.2022015423

N/A

3.0DataRank · unranked

121 citations

Hun Ju Lee, Joycelynne Palmer, Robert Chen, Ni‐Chun Tsai, Lu Chen +18 more

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

The Lancet Haematology(2022)10.1016/s2352-3026(22)00318-0

N/A

1.4DataRank · unranked

41 citations

Lu Chen, Yago Nieto, Leona Holmberg, Patrick B. Johnston, Matthew Mei +20 more

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood(2023)10.1182/blood.2023020485

N/A

1.3DataRank · unranked

40 citations

Lu Chen, James Godfrey, Joo Y. Song, Colt A. Egelston, Sandrine Puverel +18 more

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

Blood Advances(2021)10.1182/bloodadvances.2021004981

N/A

0.733DataRank · unranked

13 citations

Joycelynne Palmer, Vikram Adhikarla, Dave Yamauchi, Erasmus Poku, James R. Bading +23 more

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma

Haematologica(2023)10.3324/haematol.2023.283002

N/A

0.599DataRank · unranked

19 citations

Matthew Mei, Lu Chen, Joo Y. Song, Victoria Bedell, Elizabeth Budde +13 more

Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma

HemaSphere(2025)10.1002/hem3.70126

N/A

0DataRank · unranked

8 citations

Joycelynne Palmer, Hun Ju Lee, Iris Isufi, Robert Chen, Ni‐Chun Tsai +13 more